Table 1.

Patient histopathology and biomarker characteristics in the window-of-opportunity clinical trial

% Reductiona
PtAge/Gender/SmokerHistologyEGFRKRASCyclin D1EGFRp-EGFRNecrosis %Chronic INFbAcute INFb
163 F (Current)SCCwtwt6530905c1+1+
252 M (Never)ADExon 21wt40300302+2+
368 F (Former)ADSCCwtmut000000
471 F (Former)ADwtwt00100103+d3+
561 F (Former)ADwtmut8000401+3+
659 F (Current)BACwtmut50095000
752 F (Current)ADwtmut000403+3+
863 M (Former)BCwtwt00100301+3+
961 F (Former)ADwtmut406580203+1+
1063 M (Former)ADNANA8007552+0

Abbreviations: wt, wild-type; mut, mutant; NA, not assessed; Pt, Patients; M, Male; F, Female; SCC, squamous cell carcinoma; AD, adenocarcinoma, ADSCC, adenosquamous carcinoma; BAC, bronchioloalveolar carcinoma; BC, basaloid carcinoma; INF, inflammation.

  • aThe indicated percentages reflect the proportion of biopsies with the indicated changes in the posttreatment versus pretreatment biopsies.

  • bThe scoring system used to assess chronic and acute inflammatory changes in biopsies is described in Materials and Methods.

  • cMinimal necrosis (5%) without change in the posttreatment versus pretreatment biopsy.

  • dChronic inflammation (3+) without change in the posttreatment versus pretreatment biopsy.